Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment [Yahoo! Finance]
Taysha Gene Therapies (TSHA) had its price target raised by Canaccord Genuity Group Inc. from $14.00 to $17.00. They now have a "buy" rating on the stock.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (TSHA) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Taysha Gene Therapies (TSHA) was upgraded by Truist Financial Corporation to "strong-buy".